Compare Avalon GloboCare Corp. with Similar Stocks
Dashboard
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of -0.98% and Operating profit at 8.31% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -8.54
2
Flat results in Jun 25
3
Risky - Negative EBITDA
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
USD 4 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-1.53
229.44%
-0.89
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-13 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-89.0%
0%
-89.0%
6 Months
-85.58%
0%
-85.58%
1 Year
-91.43%
0%
-91.43%
2 Years
-98.06%
0%
-98.06%
3 Years
-99.26%
0%
-99.26%
4 Years
-99.67%
0%
-99.67%
5 Years
-99.76%
0%
-99.76%
Avalon GloboCare Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-0.98%
EBIT Growth (5y)
8.31%
EBIT to Interest (avg)
-8.54
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.76
Sales to Capital Employed (avg)
0.26
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
2.29%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-1.66
EV to EBIT
-2.50
EV to EBITDA
-2.64
EV to Capital Employed
4.51
EV to Sales
9.73
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-180.71%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 2 Schemes (0.8%)
Foreign Institutions
Held by 3 Foreign Institutions (0.02%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
0.40
0.30
33.33%
Operating Profit (PBDIT) excl Other Income
-3.80
-2.10
-80.95%
Interest
1.10
0.60
83.33%
Exceptional Items
-8.50
-0.10
-8,400.00%
Consolidate Net Profit
-13.50
-2.50
-440.00%
Operating Profit Margin (Excl OI)
-11,095.70%
-6,287.70%
-480.80%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 33.33% vs 0.00% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -440.00% vs 7.41% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1.30
1.30
Operating Profit (PBDIT) excl Other Income
-3.80
-6.90
44.93%
Interest
2.40
1.40
71.43%
Exceptional Items
0.40
0.40
Consolidate Net Profit
-7.90
-16.70
52.69%
Operating Profit Margin (Excl OI)
-3,060.70%
-5,719.60%
265.89%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 0.00% vs 8.33% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 52.69% vs -40.34% in Dec 2023
About Avalon GloboCare Corp. 
Avalon GloboCare Corp.
Pharmaceuticals & Biotechnology
Avalon GloboCare Corp. is an intelligent biotech developer and healthcare service provider. The Company engages in the management of stem cell banks and specialty clinical laboratories. It is developing of exosome technology to improve the diagnosis and management of diseases. The Company operates through two platforms, Avalon Cell and Avalon Rehab. Its technology and service ecosystem covers the areas of regenerative medicine, cell-based immunotherapy, exosome technology, as well as rehabilitation medicine. The Company also focused on diagnostic advancements in the fields of oncology, infectious diseases and fibrotic diseases, and the discovery of disease-specific exosomes to provide the disease origin insight necessary to enable.
Company Coordinates 
Company Details
4400 US Highway 9 Ste 3100 , FREEHOLD NJ : 07728-4210
Registrar Details






